Defence Therapeutics Inc. (DTC)

Overview

Defence Therapeutics Inc. is a biotechnology firm dedicated to enhancing the efficacy and safety of biological and biosimilar pharmaceuticals used in cancer and infectious disease treatments. Originally known as Accum Therapeutics Inc., the company underwent a rebranding in March 2020 to better reflect its expanded focus and capabilities in developing innovative drug delivery platforms. Founded in 2017 and based in Vancouver, Canada, Defence Therapeutics is pioneering in the field of drug enhancers with its proprietary ACCUMTM platform, aiming to set new standards in vaccine development and therapeutic treatments.

Products and Services

• Biological Drug Enhancer Platform

The ACCUMTM platform stands at the core of Defence Therapeutics Inc.’s product offerings. This innovative technology is designed to augment the efficacy and safety of a wide range of biologic and biosimilar drugs. By facilitating improved drug delivery, the ACCUMTM platform enhances the therapeutic effects of medications aimed at treating cancer and infectious diseases, potentially mitigating side effects and improving patient outcomes.

• Vaccine Development for Infectious Diseases and Viruses

Exploiting the capabilities of the ACCUMTM platform, Defence Therapeutics Inc. is actively involved in the development of vaccines targeting various infectious diseases and viruses. This initiative reflects the company's commitment to leveraging its drug delivery technology for the creation of more effective and safer vaccines. The focus on infectious diseases and viruses is particularly timely, considering the global demand for innovative solutions in combating emerging health threats.